J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval
Could Offer Option As CAR-T Manufacturing Lags
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.
You may also be interested in...
The drug maker is pointing to potential biweekly dosing as raising the possibility for the bispecific’s use in community oncology, though an expert had said it could take some time for that to happen.
R&D head Zachary Roberts spoke with Scrip about Allogene’s Phase II pivotal trial for ALLO-501A and the firm’s hopes for overcoming challenges with allogeneic CAR-T therapies in solid tumors.
Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.